elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board
elbion AG announced that Dr. Thomas Taapken has been appointed Chief Financial Officer by the supervisory board of the company.
Taapken (40), previously spent 3 years as a Partner in the life science team of DVC, Deutsche Venture Capital, and was a member of the supervisory board of elbion AG. He has resigned from DVC, and has also stepped down from his position as a supervisory board member of the company, to join elbion's management board. Prior to his position at DVC, Thomas Taapken worked for 8 years at Sanofi-Aventis in the areas of research, corporate development and venture capital. In his last position he held responsibility for the corporate venture capital activities of the group. Dr. Taapken holds a PhD in chemistry from the Technical University of Berlin.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Powerful protein promotes post-injury regeneration and growth of injured peripheral nerves

ChroMaSoft GmbH - Bad Dürkheim, Germany
